Bristol-Myers Enters Into Immuno-Oncology Collaboration with Ono Pharmaceutical

Bristol-Myers Squibb and Ono Pharmaceutical have entered into a strategic agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for cancer patients in Japan, South Korea and Taiwan.
Pharmaceutical Business Review